Gene signature and prognostic merit of M6a regulators in colorectal cancer.
Colorectal cancer
N6-methyladenosine RNA methylation
TCGA
bioinformatics
prognostic signature
Journal
Experimental biology and medicine (Maywood, N.J.)
ISSN: 1535-3699
Titre abrégé: Exp Biol Med (Maywood)
Pays: England
ID NLM: 100973463
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
2
7
2020
medline:
3
3
2021
entrez:
2
7
2020
Statut:
ppublish
Résumé
Although new diagnostic techniques and treatments are increasingly updated for CRC, the clinical outcomes of CRC patients are still not encouraging with a low survival rate. N6-methyladenosine (m6A) as a popular modification on mRNA is associated with multiple types of cancers. Our purpose is to identify gene signature and prognostic ability of m6A modulators in CRC. For the first time, we identified genetic changes of m6A modulators and built prognostic gene signature in CRC, which may provide effective targets for the diagnosis and management of CRC.
Identifiants
pubmed: 32605475
doi: 10.1177/1535370220936145
pmc: PMC7441353
doi:
Substances chimiques
Neoplasm Proteins
0
N-methyladenosine
CLE6G00625
Adenosine
K72T3FS567
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1344-1354Références
Aging (Albany NY). 2019 Feb 27;11(4):1204-1225
pubmed: 30810537
Mol Biol Rep. 2019 Apr;46(2):2567-2575
pubmed: 30911972
Crit Rev Clin Lab Sci. 2020 Jan;57(1):22-36
pubmed: 31603697
Nat Rev Genet. 2014 May;15(5):293-306
pubmed: 24662220
Oncotarget. 2017 Dec 21;9(7):7476-7486
pubmed: 29484125
Oncol Lett. 2018 Nov;16(5):5519-5524
pubmed: 30344705
Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2329-2341
pubmed: 31309275
Cancer Med. 2020 Jan;9(1):278-289
pubmed: 31701672
Mol Cancer. 2019 Nov 18;18(1):163
pubmed: 31735169
Biomed Pharmacother. 2019 Apr;112:108613
pubmed: 30784918
PeerJ. 2018 Jun 14;6:e4942
pubmed: 29915691
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Front Bioeng Biotechnol. 2018 Jul 13;6:89
pubmed: 30062093
Onco Targets Ther. 2019 Jun 04;12:4391-4402
pubmed: 31239708
Int J Mol Sci. 2019 Aug 05;20(15):
pubmed: 31387239
Cancer Lett. 2016 Jun 28;376(1):34-42
pubmed: 26996300
Virol J. 2019 Nov 11;16(1):133
pubmed: 31711514
Semin Cancer Biol. 2014 Dec;29:3-12
pubmed: 25068994
J Cell Physiol. 2019 Aug;234(10):18466-18479
pubmed: 30895618
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Mol Cancer. 2017 Apr 11;16(1):77
pubmed: 28399871
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Expert Opin Ther Targets. 2014 Aug;18(8):841-50
pubmed: 24834797
Cancer Cell Int. 2019 Jan 5;19:6
pubmed: 30627052
Front Oncol. 2019 May 03;9:332
pubmed: 31131257
Mol Cancer. 2019 Jun 24;18(1):112
pubmed: 31230592
Am J Cancer Res. 2019 Oct 01;9(10):2156-2169
pubmed: 31720080
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Exp Clin Cancer Res. 2019 Sep 6;38(1):393
pubmed: 31492150
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Aging (Albany NY). 2019 Mar 15;11(6):1633-1647
pubmed: 30877265